Abstract:Background Hepatic caveolin-1 (CAV1) is reduced in cholesterol gallstone disease (CGD). Mice with CAV1 deficiency were prone to develop CGD. However, it remains unknown whether restored hepatic CAV1 expression prevents the development of CGD. Methods C57BL/6 mice were injected with adeno-associated virus 2/8 (AAV2/8) vectors carrying the CAV1 gene ((AAV2/8)CAV1) via intravenous (i.v.) or intraperitoneal (i.p.) route and then subjected to a lithogenic diet (LD) for 8 weeks. Uninjected mice were used as controls. The functional consequences of rescuing CAV1 expression by either i.v. or i.p. (AAV2/8)CAV1 treatment for CGD prevention and its subsequent molecular mechanisms were examined. Results CAV1 expression was reduced in the liver and gallbladder of LD-fed CGD mice. We discovered that (AAV2/8)CAV1 i.p. delivery results in higher transduction efficiency in the gallbladder than tail vein administration. Although either i.v. or i.p. injection of (AAV2/8)CAV1 improved liver lipid metabolic abnormalities in CGD mice but did not affect LD feeding-induced bile cholesterol supersaturation. In comparison with i.v. administration route, i.p. administration of (AAV2/8)CAV1 obviously increased CAV1 protein levels in the gallbladder of LD-fed mice, and i.p. delivery of (AAV2/8)CAV1 partially improved gallbladder cholecystokinin receptor (CCKAR) responsiveness and impeded bile cholesterol nucleation via the activation of adenosine monophosphate-activated protein kinase (AMPK) signaling, which induced a reduction in gallbladder mucin-1 (MUC1) and MUC5ac expression and gallbladder cholesterol accumulation. Conclusion CGD prevention by i.p. (AAV2/8)CAV1 injection in LD-fed mice was associated with the improvement of gallbladder stasis, which again supported the notion that supersaturated bile is required but not sufficient for the formation of cholesterol gallstones. Additionally, AAV treatment via the local i.p. injection offers particular advantages over the systemic i.v. route for much more effective gallbladder gene delivery, which will be an excellent tool for conducting preclinical functional studies on the maintenance of normal gallbladder function to prevent CGD.

mRNA expression of hepatic cannalicular ABC transporters in patients with cholesterol gallstone disease

Expression of liver receptor homolog 1 and its regulating abcg5/8 genes in patients with gallstone

Mrna Expression of Liver Nuclear Receptor Genes in Patients with Cholesterol Gallstone Disease

Study on the relationship between the gene expression of ABCG5 and ABCG8 in gallbladder mucosa and the pathogenesis of gallbladder cholesterol polyps

The mRNA expression of hepatic scavenger receptor B type I and liver receptor homologue 1 in Patients with cholesterol gallstone disease

Expression of ABCG1 in gallbladder mucosa in patients with cholesterol polyps

Relation of ABCG5 and ABCG8 to Formation of Cholesterol Gall Stone

Increased expression of LXRα, ABCG5, ABCG8, and SR-BI in the liver from normolipidemic, nonobese Chinese gallstone patients Published, JLR Papers in Press, November 15, 2007.

Increased NPC1L1 and ACAT2 Expression in the Jejunal Mucosa from Chinese Gallstone Patients.

Preliminary Study on Expression Genes Involved in Intestinal Cholesterol Absorption in Patients with Gallstone

Characteristics of serum lipids,leptin,cholecystokinin and bile lipids in patients with cholecystolithiasis

Identification of the molecular defects in the liver underlying gallstone disease in non-obese Chinese patients

Expression of liver receptor homolog 1 gene in patients with cholesterol gallstone disease

Expression and Its Significance of Caveolin–1 in Liver and Gallbladder of Gallstone Mice Model

Characteristics of Mrna Levels of Hepatic Cholesterol Metabolism Regulatory Enzymes in Genetically Gallstone-Susceptible and Resistant Mice

Impaired regulation of sterol regulatory element binding protein 2 in cholesterol gallstone-susceptible mice.

The relationship between ABCA1 gene expression in gallbladder mucosa and the genesis of gallbladder cholesterol polyps

Effect of Hepatic NPC1L1 on Cholesterol Gallstone Disease and Its Mechanism

Differences Between Hepatic and Biliary Lipid Metabolism and Secretion in Genetically Gallstone-Susceptible and Gallstone-Resistant Mice

Adeno-associated Virus-Based Caveolin-1 Delivery Via Different Routes for the Prevention of Cholesterol Gallstone Formation

Difference in Expression of Genes in Gallbladder Wall in Patients with Cholesterol Gallstone Disease